Valeant move on heart drug rebates 'small step'-top U.S. House Democrat

Mon May 16, 2016 10:35am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

WASHINGTON May 16 (Reuters) - Valeant Pharmaceuticals International Inc's decision to lower costs for two of its heart drugs is a small positive step but does not address high prices for its other products, the top Democrat on the U.S. House of Representatives' oversight panel said on Monday.

"This is a small step in the right direction, but it comes nowhere close to fully addressing this critical problem," Representative Elijah Cummings said in a statement, adding that "Valeant also made no mention of its massive price increases on other drugs." (Reporting by Susan Heavey; Editing by Jeffrey Benkoe)